Search results for "TRoponin I"
showing 3 items of 73 documents
Concomitant history of cancer in acute pulmonary embolism is connected with poorer outcome
2015
Abstract Purpose: Cancer increases the risk of venous thromboembolism (VTE) substantially. VTE is connected with poorer outcome in cancer patients. The aim of our study was to investigate the impact of cancer on the severity and short-term outcome of pulmonary embolism (PE). Methods: We retrospectively analyzed the data of 182 patients with confirmed PE. PE patients were subdivided in the group with concomitant active cancer disease or history of cancer or in the group without cancer. Groups were compared with Wilcoxon–Mann–Whitney Test. Logistic regression models were calculated to investigate the association between cancer and several parameters such as age and PE severity status as well …
0201: Cardiac surgery associated with cardiopulmonary bypass in patients with stable coronary disease: growth differentiation factor-15 (GDF- 15) as …
2014
BackgroundGrowth differentiation factor-15 (GDF-15) has been identified as a strong marker for cardiovascular disease; however, no data are available concerning the role of GDF-15 in the occurrence of organ dysfunction during cardiac surgery associated with cardiopulmonary bypass (CPB).MethodsThirty four patients, programmed to have non-urgent coronary artery bypass grafting (CABG), were included in our study. Arterial blood samples were taken sequentially from anesthesia induction (IND) until 24h after arrival at the cardiovascular intensive care unit (ICU). Plasma levels of GDF-15, follistatin-like 1 (FLST1), myeloperoxidases (MPO), hydroperoxides and plasma antioxidant status (PAS) were …
Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity
2011
Normal tissue damage limits the efficacy of anticancer therapy. For anthracyclines, the clinically most relevant adverse effect is cardiotoxicity. The mechanisms involved are poorly understood and putative cardioprotectants are controversially discussed. Here, we show that the lipid-lowering drug lovastatin protects rat H9c2 cardiomyoblasts from doxorubicin in vitro. Protection by lovastatin is related to inhibition of the Ras-homologous GTPase Rac1. It rests on a reduced formation of DNA double-strand breaks, resulting from the inhibition of topoisomerase II by doxorubicin. Doxorubicin transport and reactive oxygen species are not involved. Protection by lovastatin was confirmed in vivo. I…